Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, 221 85, Lund, Sweden.
Breast Cancer Res Treat. 2010 Jul;122(2):315-24. doi: 10.1007/s10549-009-0568-x. Epub 2009 Oct 1.
Decreased expression of Numb, resulting in activation of the proto-oncogene Notch1 and reduction in the tumor suppressor p53, has been demonstrated in mammary carcinomas. The aim of this study was to investigate the relationship between Numb protein expression and clinicopathological characteristics, tumor biological subtypes and putative cancer stem cell markers in a well-characterized cohort of primary human breast cancers. Immunohistochemistry was performed on tissue microarrays of primary invasive breast tumors using a polyclonal anti-Numb primary antibody. Of the 241 tumors evaluated, 50 (21%) displayed deficient or reduced Numb immunoreactivity. Retained Numb expression was significantly correlated to estrogen (ER) and progesterone receptor (PR) positivity (P < 0.001 and P = 0.004, respectively). Interestingly, we found that a higher percentage of the tumors with deficient or reduced Numb expression belonged to the triple-negative (ER-/PR-/HER2-) subgroup compared to tumors with retained Numb expression (P = 0.004). Transcriptional profiling of a subset of these tumors linked NOTCH1 and BIRC5, both downstream targets of Numb, to the triple-negative subgroup in an inverse manner. Typically, subgroups characterized by the low expression of Numb expressed higher levels of NOTCH1 and BIRC5 (encoding survivin). We also found deficient expression of Numb in a significantly higher proportion of BRCA1 dependent tumors, which are usually triple-negative, compared to sporadic tumors. The expression of Numb in 14 breast cancer cell lines correlated similarly to their respective molecular subtypes. We further established an inverse correlation between the Numb expression levels and the CD44+/CD24- cancer stem cell phenotype (P = 0.05) in primary tumors. Finally, decreased Numb expression was associated with poorer distant disease-free survival (P = 0.01). Taken together, our results indicate that loss of Numb expression is a marker of tumor aggressiveness, potentially linked to BRCA1 status and a cancer stem cell phenotype in primary breast cancer.
在乳腺癌中已经证实,Numb 的表达减少导致原癌基因 Notch1 的激活和肿瘤抑制因子 p53 的减少。本研究的目的是在一组特征明确的原发性人类乳腺癌中研究 Numb 蛋白表达与临床病理特征、肿瘤生物学亚型和潜在的癌症干细胞标志物之间的关系。使用多克隆抗 Numb 抗体对原发性浸润性乳腺癌组织微阵列进行免疫组织化学染色。在评估的 241 个肿瘤中,有 50 个(21%)显示 Numb 免疫反应性缺乏或降低。保留的 Numb 表达与雌激素(ER)和孕激素受体(PR)阳性显著相关(P<0.001 和 P=0.004)。有趣的是,我们发现与保留 Numb 表达的肿瘤相比,缺乏或降低 Numb 表达的肿瘤中,更高比例的肿瘤属于三阴性(ER-/PR-/HER2-)亚组(P=0.004)。对这些肿瘤的亚组进行转录谱分析表明,Numb 的下游靶标 NOTCH1 和 BIRC5 与三阴性亚组呈负相关。通常,Numb 低表达的亚组表达更高水平的 NOTCH1 和 BIRC5(编码 survivin)。我们还发现,与散发性肿瘤相比,BRCA1 依赖性肿瘤中 Numb 的表达缺陷比例更高,这些肿瘤通常是三阴性的。14 种乳腺癌细胞系中 Numb 的表达与它们各自的分子亚型相似。我们进一步在原发性肿瘤中建立了 Numb 表达水平与 CD44+/CD24-癌症干细胞表型之间的负相关(P=0.05)。最后,Numb 表达减少与远处无病生存率较差相关(P=0.01)。综上所述,我们的研究结果表明,Numb 表达缺失是肿瘤侵袭性的标志物,可能与 BRCA1 状态和原发性乳腺癌中的癌症干细胞表型有关。